• Vaccine Name: Dodecin–ESAT-6
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: The antigen is dodecin–ESAT-6 fusion protein, composed ESAT-6 (Rv3875) and fused to the dodecameric flavin-binding protein dodecin (Rv1498A) (Zhao et al., 2021).
• EsxA (ESAT-6) gene engineering:
  • Type: Fusion Protein
  • Description: Used in preparation of fusion protein (Zhao et al., 2021).
  • Detailed Gene Information: Click Here.
• RV1498A gene engineering:
  • Type: Fusion Protein
  • Description: Used in preparation of fusion protein
  • Detailed Gene Information: Click Here.
• Preparation: The dodecin–ESAT-6 fusion protein was generated by PCR amplification and SOEing fusion of the Rv1498A and Rv3875 genes, cloned into the pET-28a expression vector, expressed in Escherichia coli Rosetta (DE3), purified by His-tag affinity chromatography, and subjected to endotoxin removal prior to immunization (Zhao et al., 2021).
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: BALB/c
• Host gender: Female
• Vaccination Protocol: Mice were immunized subcutaneously at weeks 0, 3, and 6 with 20 µg of dodecin–ESAT-6 formulated with the DDA/MPL (DPL) adjuvant, and immune responses were assessed four weeks after the final dose (Zhao et al., 2021).
• Immune Response: Immunization with dodecin–ESAT-6 elicited enhanced antigen-specific CD4⁺ and CD8⁺ T cell responses, increased IFN-γ and IL-2 secretion, reduced IL-4 production, and elevated IgG and IgG2a antibody titers, indicating a predominantly Th1-type immune response(Zhao et al., 2021).
• Description: Dodecin–ESAT-6 vaccine enhance antigen presentation and induce strong Th1-skewed immune responses (Zhao et al., 2021).
• Information about this animal model: Mouse Model for TB research